The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer

Stopped early · Not applicable

Conditions studied: Cryotherapy Effect, Peripheral Neuropathy, Nail Toxicity

In brief

This study will determine the efficacy of cryotherapy to prevent paclitaxel-induced peripheral neuropathy and nail changes in women with breast cancer.

Key facts

Study ID

NCT04558034

Run by

Parkview Health

People needed

14

Starts

2020-08-04

Expected to finish

2021-02-03

Last updated by the study team

2021-03-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females 18 or older
• Histologically confirmed diagnosis of breast cancer
• Receiving neo-adjuvant or adjuvant dose-dense anthracycline (AC) plus taxane-based chemotherapy or paclitaxel in combination with trastuzumab and pertuzumab

You may not qualify if…

• Prior taxane therapy
• Prior oxaliplatin therapy
• Non-English speaking
• History of peripheral neuropathy, i.e., Buerger's disease
• History of diabetes mellitus
• Pre-existing peripheral neuropathy from other conditions, e.g., Raynaud's disease, Guillain-Barre, Miller Fisher Syndrome
• Hand, nail or foot conditions, e.g., hand/foot syndrome, arthritis, hammer toe, carpal tunnel, bunions, deformities
• Alcohol abuse (history/current)
• Current medication usage of opioids, anti-depressants, anti-convulsants, glutamines, vitamin B12

Where it is running

• Parkview Cancer Institute — Fort Wayne, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.